CLINICAL TRIALS PROFILE FOR CHLORPHENIRAMINE MALEATE
✉ Email this page to a colleague
All Clinical Trials for chlorpheniramine maleate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00555542 ↗ | An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis | Completed | Chinese University of Hong Kong | Phase 2 | 2006-07-01 | To study the effects of T cell in peripheral blood of patients with RA undergoing selective B cell depletion have not been studied. We analyze the B and T cell subsets in patients with active RA treated undergoing this form of treatment with rituximab. |
| NCT00837837 ↗ | Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2008-12-21 | The purpose of this study is to examine the pharmacokinetic parameters of chlorpheniramine in children and adolescents. |
| NCT01158326 ↗ | Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu | Completed | Hospital de Clinicas de Porto Alegre | Phase 3 | 2010-08-01 | This study aimed to evaluate the efficacy and safety of the oral solution of paracetamol, chlorpheniramine maleate and phenylephrine hydrochloride in reducing symptoms of flu and the common cold. There will be a randomized, double-blind, placebo-controlled trial. Will be included 216 subjects, male or female, aged greater than 12 and less than or equal to 60 years, irrespective of color and / or race with symptoms of recent onset, for more than 6 hours and less than 48 hours length, characterizing Common Cold and / or Influenza. After clinical evaluation and laboratory research subjects will be randomized to receive active drug or placebo, 10 ml oral solution every 6 hours for 48 hours. The follow-up visits will be held on 2 (24 hours after first intervention) and in 3 days (48 hours after first intervention). The outcomes to assess the effectiveness so far consist of the scores of symptoms and to assess the safety of the drug will be accompanied by the emergence of adverse events. |
| NCT01293201 ↗ | Trial of STAHIST in Seasonal Allergic Rhinitis | Completed | Magna Pharmaceuticals, Inc. | Phase 3 | 2011-03-01 | The overall development plan is to show that the combination of tried-and-proven decongestant/antihistamine ingredients (pseudoephedrine hydrochloride and chlorpheniramine maleate), plus a very small amount of belladonna alkaloids (.24 mg atropine sulfate) is a comprehensive, safe and effective B.I.D. drug treatment regimen, indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Treated symptoms include nasal congestion, sneezing, rhinorrhea, itchy nose, itchy/watery eyes, and post nasal drip syndrome [reduction in tickly cough (acute or chronic), mucus in the back of the throat, sore throat, and hoarseness]. Considering the favorable safety and efficacy results of Phase 1 and Phase 2, the purpose of Phase 3 is to assess and compare the safety and efficacy of the study drug in a larger group comparatively with a placebo control group. Objectives: A) To report and compare total symptom scores (TSS) by SAR subjects rating the efficacy of STAHIST vs. placebo in relieving nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip over the two-week study period. B) Report any side effects or adverse drug reactions and rate the severity of any incident. C) Compare and report each symptom score, total nasal symptom scores (TNSS), and post-nasal drip symptom scores (PND-S) between the two study arms. |
| NCT01393548 ↗ | Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis | Completed | Ache Laboratorios Farmaceuticos S.A. | Phase 3 | 2014-08-01 | This is a multicenter clinical trial, phase III, non-inferiority, controlled by active medicine, open, randomized, enroll 538 children, 2 to 12 years old, with acute inflammation upper airway, characterized by nasal congestion and runny nose, lasting at least 24 hours and a maximum of 48 hours prior to inclusion. The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for chlorpheniramine maleate
Condition Name
Clinical Trial Locations for chlorpheniramine maleate
Trials by Country
Clinical Trial Progress for chlorpheniramine maleate
Clinical Trial Phase
Clinical Trial Sponsors for chlorpheniramine maleate
Sponsor Name
